We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Analyst Projections for Key Metrics Reveal About Ultragenyx (RARE) Q4 Earnings
Read MoreHide Full Article
Analysts on Wall Street project that Ultragenyx (RARE - Free Report) will announce quarterly loss of $1.65 per share in its forthcoming report, representing an increase of 23.6% year over year. Revenues are projected to reach $122.71 million, increasing 18.7% from the same quarter last year.
The current level reflects an upward revision of 1.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Ultragenyx metrics that are commonly monitored and projected by Wall Street analysts.
Analysts expect 'Revenues- Product sales- Mepsevii' to come in at $7.45 million. The estimate suggests a change of +55.2% year over year.
The consensus among analysts is that 'Revenues- Product sales- Dojolvi' will reach $21.99 million. The estimate points to a change of +34% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Product sales' reaching $54.69 million. The estimate suggests a change of +89.2% year over year.
The consensus estimate for 'Revenues- Non-cash collaboration royalty revenue' stands at $72.81 million. The estimate indicates a year-over-year change of +1101.9%.
Ultragenyx shares have witnessed a change of +2.3% in the past month, in contrast to the Zacks S&P 500 composite's +5.8% move. With a Zacks Rank #3 (Hold), RARE is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What Analyst Projections for Key Metrics Reveal About Ultragenyx (RARE) Q4 Earnings
Analysts on Wall Street project that Ultragenyx (RARE - Free Report) will announce quarterly loss of $1.65 per share in its forthcoming report, representing an increase of 23.6% year over year. Revenues are projected to reach $122.71 million, increasing 18.7% from the same quarter last year.
The current level reflects an upward revision of 1.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Ultragenyx metrics that are commonly monitored and projected by Wall Street analysts.
Analysts expect 'Revenues- Product sales- Mepsevii' to come in at $7.45 million. The estimate suggests a change of +55.2% year over year.
The consensus among analysts is that 'Revenues- Product sales- Dojolvi' will reach $21.99 million. The estimate points to a change of +34% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Product sales' reaching $54.69 million. The estimate suggests a change of +89.2% year over year.
The consensus estimate for 'Revenues- Non-cash collaboration royalty revenue' stands at $72.81 million. The estimate indicates a year-over-year change of +1101.9%.
View all Key Company Metrics for Ultragenyx here>>>
Ultragenyx shares have witnessed a change of +2.3% in the past month, in contrast to the Zacks S&P 500 composite's +5.8% move. With a Zacks Rank #3 (Hold), RARE is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>